IRVINE, Calif., Jan. 28, 2004 (PRIMEZONE) -- Trimedyne, Inc. (OTCBB:TMED) today announced its chairman, Marvin P. Loeb, was interviewed by MacReport.Net. The interview will be available by visiting http://www.macreport.net/ and entering "TMED" in the public companies section.
Mr. Loeb discussed Trimedyne's business, including its current product lines, new products in development and the Company's plans for the future.
Commenting on the interview, Mr. Loeb said, "We are pleased that MacReport chose to interview us, and we are gratified by the attention being paid to Trimedyne's continued profitability and the potential of its new products. Trimedyne has demonstrated its ability to develop innovative, patented products, effectively market them and earn $1 million or $.07 per share, fully diluted, in the year ended September 30, 2003."
About MacReport.net.
MacReport.Net is an information and media company that provides a Web-based forum for public and private issuers to communicate corporate audio and video news content to the business, financial and investing community through its Web site, located at http://www.macreport.net/
About Trimedyne, Inc.
Trimedyne is a leading manufacturer of proprietary surgical lasers and disposable and reusable fiber optic devices for minimally invasive procedures in orthopedics (arthroscopy and new, outpatient procedures to treat herniated and ruptured spinal discs), lithotripsy (fragmentation of stones in the kidney, ureter and bladder) and a variety of applications in ENT surgery, gynecology, gastrointestinal surgery and general surgery. For additional information, visit Trimedyne's website at http://www.trimedyne.com/
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:
Statements in this news release and the above mentioned interview may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-K-SB and subsequently filed SEC reports. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.